Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (421-430 of 466) with videos related to

Pageof 47
Sort By:
Cancer Research|October 23, 2021
Activation of <i>Notch</i> and <i>Myc</i> Signaling via B-cell-Restricted Depletion of <i>Dnmt3a</i> Generates a Consistent Murine Model of Chronic Lymphocytic LeukemiaAnat Biran, Shanye Yin, Helene Kretzmer, et al.
The New England Journal of Medicine|June 6, 2019
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ConditionsKirsten Fischer, Othman Al-Sawaf, Jasmin Bahlo, et al.
Nature|October 16, 2015
Mutations driving CLL and their evolution in progression and relapseDan A Landau, Eugen Tausch, Amaro N Taylor-Weiner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2024
End Point Surrogacy in First-Line Chronic Lymphocytic LeukemiaFlorian Simon, Rudy Ligtvoet, Sandra Robrecht, et al.
Blood|October 5, 2018
IG-<i>MYC</i> <sup>+</sup> neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomasRabea Wagener, Cristina López, Kortine Kleinheinz, et al.
Blood|September 4, 2025
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trialFlorian Simon, Rudy Ligtvoet, Jan-Paul Bohn, et al.
Haematologica|January 18, 2015
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic LeukemiaCarol Moreno, Marco Montillo, Panayiotis Panayiotidis, et al.
Blood|April 16, 2025
International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC RecommendationsAdam S Kittai, Monia Marchetti, Othman Al-Sawaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2024
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 TrialPetra Langerbeins, Sandra Robrecht, Pascal Nieper, et al.
Lancet (London, England)|June 18, 2016
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Eva Hoster, Jan Walewski, et al.
Pageof 47

Showing results (421-430 of 466) with videos related to

Sort By:
Pageof 47
Cancer Research|October 23, 2021
Activation of <i>Notch</i> and <i>Myc</i> Signaling via B-cell-Restricted Depletion of <i>Dnmt3a</i> Generates a Consistent Murine Model of Chronic Lymphocytic LeukemiaAnat Biran, Shanye Yin, Helene Kretzmer, et al.
The New England Journal of Medicine|June 6, 2019
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting ConditionsKirsten Fischer, Othman Al-Sawaf, Jasmin Bahlo, et al.
Nature|October 16, 2015
Mutations driving CLL and their evolution in progression and relapseDan A Landau, Eugen Tausch, Amaro N Taylor-Weiner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 30, 2024
End Point Surrogacy in First-Line Chronic Lymphocytic LeukemiaFlorian Simon, Rudy Ligtvoet, Sandra Robrecht, et al.
Blood|October 5, 2018
IG-<i>MYC</i> <sup>+</sup> neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomasRabea Wagener, Cristina López, Kortine Kleinheinz, et al.
Blood|September 4, 2025
Acalabrutinib treatment for older (≥80 years old) and/or frail patients with CLL: primary end point analysis of the CLL-Frail trialFlorian Simon, Rudy Ligtvoet, Jan-Paul Bohn, et al.
Haematologica|January 18, 2015
Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic LeukemiaCarol Moreno, Marco Montillo, Panayiotis Panayiotidis, et al.
Blood|April 16, 2025
International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: the ERIC RecommendationsAdam S Kittai, Monia Marchetti, Othman Al-Sawaf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 27, 2024
Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 TrialPetra Langerbeins, Sandra Robrecht, Pascal Nieper, et al.
Lancet (London, England)|June 18, 2016
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Eva Hoster, Jan Walewski, et al.
Pageof 47